{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:27Z","timestamp":1740106887849,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bisphosphonate use is associated with atypical non-traumatic fractures, which are most commonly seen in the femur.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>We report a 63-year-old postmenopausal woman who presented acutely with progressively worsening lumbar pain radiating to her left hip for 10\u00a0days. There was no antecedent trauma. On examination, the patient could not bear weight on her left leg due to the severity of the pain. Radiography and computed tomography of the pelvis demonstrated an iliac wing fracture which was treated conservatively. The patient had a significant past medical history of breast cancer and intense bisphosphonate use for several years which was discontinued 3\u00a0years previously. No discrete bone lesion was seen at the fracture site on computed tomography, and there was no evidence of metastatic disease elsewhere. A dual-energy X-ray absorptiometry scan showed the lowest bone mineral density <jats:italic>T<\/jats:italic>-score of\u2009\u2212\u20091.2. A diagnosis of an atypical fracture related to long-term bisphosphonate therapy was made.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>To the best of our knowledge, this is the first reported case of an isolated iliac wing fracture associated with long-term bisphosphonate therapy in the literature. Whilst the incidence of such fractures is exceedingly rare, it is an important differential in patients with atypical fractures on long-term bisphosphonates.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00256-024-04738-9","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T06:01:50Z","timestamp":1721455310000},"page":"627-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe atypical iliac wing fracture associated with long-term bisphosphonate use"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-5377","authenticated-orcid":false,"given":"John","family":"Kelliher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"4738_CR1","volume-title":"Bisphosphonates in bone disease: From the laboratory to the patient","author":"H Fleisch","year":"2000","unstructured":"Fleisch H. Bisphosphonates in bone disease: From the laboratory to the patient. San Diego: Academic Press; 2000."},{"issue":"8","key":"4738_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/nejmoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743\u201353. https:\/\/doi.org\/10.1056\/nejmoa1916525.","journal-title":"N Engl J Med"},{"issue":"8","key":"4738_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729\u201337.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4738_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2013","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and mineral research. J Bone Miner Res. 2013;29(1):1\u201323.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4738_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/17453670903139914","volume":"80","author":"J Schilcher","year":"2009","unstructured":"Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80(4):413\u20135. https:\/\/doi.org\/10.3109\/17453670903139914.","journal-title":"Acta Orthop"},{"issue":"3","key":"4738_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4738_CR7","first-page":"251","volume":"13","author":"V Patel","year":"2013","unstructured":"Patel V, Graves L, Lukert B. Pelvic fractures associated with long-term bisphosphonate therapy - case report. J Musculoskelet Neuronal Interact. 2013;13(2):251\u20134.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"4738_CR8","first-page":"bcr2014206319","volume":"2014","author":"HI Watson","year":"2014","unstructured":"Watson HI, Hopper GP, Gupta S, Roberts JL. Pathological pelvic fracture following long-term bisphosphonate use in a 63-year-old woman. Case Reports. 2014;2014:bcr2014206319.","journal-title":"Case Reports."},{"key":"4738_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1530-891X(20)47195-2","volume":"24","author":"B Varghese","year":"2018","unstructured":"Varghese B, Falk C, Haroon NN. Abstract #518 atraumatic pelvic fractures associated with bisphosphonate therapy. Endocr Pract. 2018;24:115\u20136.","journal-title":"Endocr Pract"},{"issue":"1","key":"4738_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","volume":"85","author":"R Armamento-Villareal","year":"2009","unstructured":"Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: A case series. Calcif Tissue Int. 2009;85(1):37\u201344.","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"4738_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00774-007-0771-y","volume":"25","author":"K Imai","year":"2007","unstructured":"Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by Alendronate Therapy. J Bone Miner Metab. 2007;25(5):333\u20136.","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"4738_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"DM Black","year":"2018","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and Clinical Management. Endocr Rev. 2018;40(2):333\u201368. https:\/\/doi.org\/10.1210\/er.2018-00001.","journal-title":"Endocr Rev"},{"issue":"1","key":"4738_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69(1):73\u201382. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.07.013.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"4738_CR14","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/nejmoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with Zoledronic acid. N Engl J Med. 2011;365(15):1396\u2013405. https:\/\/doi.org\/10.1056\/nejmoa1105195.","journal-title":"N Engl J Med"},{"issue":"2","key":"4738_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/jcem.85.2.6393","volume":"85","author":"HG Bone","year":"2000","unstructured":"Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density1. J Clin Endocrinol Metab. 2000;85(2):720\u20136. https:\/\/doi.org\/10.1210\/jcem.85.2.6393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4738_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jocd.2019.07.003","volume":"22","author":"AM Cheung","year":"2019","unstructured":"Cheung AM, McKenna MJ, van de Laarschot DM, et al. Detection of atypical femur fractures. J Clin Densitom. 2019;22(4):506\u201316.","journal-title":"J Clin Densitom"},{"key":"4738_CR17","unstructured":"The International Society for Clinical Densitometry (ISCD). Adult positions: indications for bone mineral density (BMD) testing. 2023. [Cited 2023 May 10]. Available from: https:\/\/iscd.org\/learn\/official-positions\/adult-positions\/."},{"issue":"3","key":"4738_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4140\/tcp.n.2017.144","volume":"32","author":"CM Deas","year":"2017","unstructured":"Deas CM, Murphy P, Iranikhah M, Freeman MK. Retained skeletal effects of zoledronic acid following discontinuation of treatment: A review of the literature. Consult Pharm. 2017;32(3):144\u201355. https:\/\/doi.org\/10.4140\/tcp.n.2017.144.","journal-title":"Consult Pharm"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-024-04738-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:35:07Z","timestamp":1737992107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-024-04738-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["4738"],"URL":"https:\/\/doi.org\/10.1007\/s00256-024-04738-9","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"type":"print","value":"0364-2348"},{"type":"electronic","value":"1432-2161"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the subject described in this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}